Oct 2026· International Health Sciences Review· 0 citations
TL;DR
This narrative critical review examines the effectiveness of intravitreal vascular endothelial growth factor (VEGF) inhibition and the clinical, structural, and treatment-related characteristics associated with visual and anatomical response.
Abstract
Diabetic macular edema (DME) is a major cause of visual impairment in people with diabetes, but eyes with similar retinal thickness can follow different courses during treatment. This narrative critical review examines the effectiveness of intravitreal vascular endothelial growth factor (VEGF) inhibition and the clinical, structural, and treatment-related characteristics associated with visual and anatomical response. PubMed/MEDLINE-indexed clinical trials, secondary analyses, observational cohorts, evidence syntheses, and current professional recommendations were examined through 2026, with particular attention to center-involved DME. Randomized trials support anti-VEGF treatment for most eyes with reduced visual acuity, although the comparative advantage of individual agents depends partly on pretreatment vision and the treatment strategy. Faricimab and higher-dose aflibercept can extend injection intervals in selected patients without sacrificing short- to medium-term visual efficacy under trial conditions. Baseline acuity, age, glycemic status, and prior retinal damage help explain outcome variation. Optical coherence tomography features, especially inner retinal disorganization and photoreceptor-layer disruption, provide prognostic information, but they do not yet establish a validated algorithm for selecting a specific drug. Early functional response is informative, whereas residual thickness alone should not define failure. Effective individualization requires repeated assessment of acuity, retinal morphology, treatment exposure, and feasibility of follow-up.
Age-related macular degeneration (AMD) is a major threat to central vision in later life, and neovascular AMD can rapidly compromise reading, face recognition, mobility, driving, medication management, and other activities that support independent living. This narrative review examines how intravitreal anti-vascular en...
Felipe Leandro Merhi, Paulo Cézar Farias, Luiza Moreira Coelho et al.· International Health Science...· 0 citations
It is suggested that the chronic use of exogenous insulin may not influence the functional or anatomic response to anti-VEGF injections in diabetic patients on chronic exogenous insulin therapy.
Jonathan D. Groothoff, Annie G. Elander, Sean K. Wang et al.· Graefe's archive for clinica...· 0 citations
INTRODUCTION
Diabetic macular edema (DME) is a major cause of vision loss among working‑age adults in the United States. Currently, intravitreal anti-vascular endothelial growth factor (anti‑VEGF) injections are the first‑line pharmacological treatment for the management of center‑involving DME. However, real‑world out...
Charles Zhang, Sinan Ersan, Abdullah Virk et al.· Expert Opinion on Emerging D...· 0 citations
Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss among older adults. Although randomised controlled trials have demonstrated the robust efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, real-world outcomes often differ mar...
M. Suleimenov, B. Kadyrgaliyev, E. Kanafyanova et al.· Vision· 0 citations